GlassScriptPhysician profile
Derek K Soohoo
NPI 1588738868
$5,902.20
in general payments reported to CMS, 2019-2025
37 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $434 · 2021: $641 · 2022: $992 · 2023: $1,396 · 2024: $953 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,219.11 | 2020-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $1,127.33 | 2019-2025 | |
| Genzyme Corporation | $1,061.56 | 2019-2025 | |
| Optinose US, INC. | $481.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.47 | 2019-2025 | Fasenra |
| Pfizer INC. | $180.05 | 2022-2024 | |
| Inspire Medical Systems, INC. | $174.33 | 2023-2025 | Inspire |
| Hikma Pharmaceuticals USA | $165.01 | 2022-2024 | Ryaltris |
| Alk-Abello, INC | $158.72 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $138.85 | 2022-2025 | Cuvitru, Hyqvia |
| Grifols USA, LLC | $134.92 | 2023-2025 | Xembify, Gamunex-C |
| Medtronic, INC. | $98.55 | 2023-2025 | Propel, Sinuva, Stealthstation S8 Platform |
| Stryker Corporation | $94.95 | 2019 | |
| Csl Behring | $60.11 | 2021-2023 | Hizentra |
| Aerin Medical INC. | $45.56 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.33 | 2022-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.43 | 2022 | |
| Acclarent, INC | $35.53 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.33 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $28.25 | 2025 | Ebglyss, Taltz |
| Integra Lifesciences Corporation | $27.21 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Ars Pharmaceuticals Operations, INC. | $25.36 | 2025 | Neffy |
| Pharming Healthcare, INC. | $23.19 | 2022 | |
| Blueprint Medicines Corporation | $21.47 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $20.70 | 2023 | |
| Amgen INC. | $19.64 | 2021 | |
| Abbvie INC. | $19.24 | 2025 | |
| Kaleo, INC. | $18.47 | 2024 | Auvi-Q |
| Medtronic USA, INC. | $17.55 | 2019 | |
| Smith+Nephew, INC. | $17.26 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2020 | |
| Phadia US INC. | $15.25 | 2023 | Immunocap |
| Eyevance Pharmaceuticals LLC | $14.50 | 2021 | |
| Bio Products Laboratory USA, INC. | $14.37 | 2022 | |
| Incyte Corporation | $13.63 | 2022 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Soohoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.